Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This study involves the use of a drug called Thymoglobulin, which is approved in the US to
treat kidney transplant rejection and in Canada to treat and prevent kidney transplant
rejection. This study will evaluate the effect of Thymoglobulin induction therapy and reduced
doses of calcineurin inhibitors on the incidence of liver rejection and will provide a basis
for future evaluations of Thymoglobulin as an immunosuppressive agent to help decrease the
incidence of liver transplant rejection. Subjects meeting all inclusion and exclusion
criteria are eligible to participate in this study. Approximately 75 study subjects from up
to 18 transplant centers in the United States and Canada will be enrolled in this 12-month
study.